All In Biotech

Drug Trial Radar · NCT07052006

A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia

A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndrome (MDS) and Symptomatic Anemia

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

37

Actual

Start

Dec 9, 2023

Primary completion

Jan 8, 2026

Study completion Sep 30, 2026

Sponsor

Lead sponsor
Halia Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jul 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research is being conducted to asses if HT-6184 is effective in the treatment of Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) and Symptomatic Anemia. The study includes a 28-day Screening Period followed by a 16- or 32-week Treatment Period. Participants will be monitored at each cycle for drug tolerance, safety, and hematological response. A response assessment will occur after 16 weeks of study treatment.

Conditions

  • Myelodysplastic Syndrome
  • Anemia in Myelodysplastic Syndromes

Interventions

  • HT-6184Drug

    Oral HT-6184

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The rate of hematological improvement.Time frame: 16 weeks

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Hemato Oncology Clinica Ahmedabad Pvt. Ltd. Vedanta Institute of Medical Sciences

    Ahmedabad, Gujarat, India

  • Shalby Hospital

    Ahmedabad, Gujarat, India

  • Malabar Cancer Center

    Kannur, Kerala, India

  • HCG Cancer Center Vizag

    Visakhapatnam, Krishna, India

  • Dr. Bafna's Star Superspeciality Clinic and Hospital

    Kolhāpur, Maharashtra, India

  • All India Institute of Medical Sciences

    Dehradun, Rishkesh, India

  • Meenakshi Mission Hospital and Research Centre

    Madurai, Tamil Nadu, India

  • Apollo Cancer Centre

    Hyderabad, Telangana, India

  • Nil Ratan Sircar Medical College and Hospital

    Kolkata, West Bengal, India

  • Tata Medical Center

    Kolkata, West Bengal, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.